Trial
NCT00361296
Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
National Cancer Institute (NCI); Alliance for Cancer Gene Therapy
Condition
Myelodysplastic Syndromes
Intervention
K562/GM-CSF cell vaccine
Why stopped
Loss of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-23